Two clinical trials are on-going in France, aiming at optimizing 68Ga-IMP288 and the anti-CEA trivalent humanized TF2 BsMAb molar doses and pretargeting delay for immuno-PET in patients with relapsed MTC or HER2-negative BC. Here, ERBB2 is linked to breast cancer.